Amarin Corp Plc (AMRN) — Analysis Summary
Amarin Corp Plc (AMRN) has a market cap of $243.55M with year-over-year revenue growth of -6.5%. Net margin stands at -18.2%. The stock trades at a P/E ratio of -9.0.
Key Takeaways
- Revenue changed -6.5% year-over-year
- Net margin of -18.2%
- P/E ratio of -9.0
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, AMRN posted revenue growth of -6.5% and trades at a P/E of -9.0.
Amarin Corp Plc (AMRN)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating margin at -21.9% — material operating losses
Revenue declined 12.8% vs the prior period.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
80
Headquarters
DUBLIN 2
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.